Tharimmune to Present at 2024 BIO International Convention

29 May 2024
License out/inImmunotherapy
BRIDGEWATER, NJ / ACCESSWIRE / May 29, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announces that management will be presenting at the 2024 BIO International Convention being held June 3-6, 2024 in San Diego. The Company will be presenting at the convention and will hold 1x1 meetings with investors and industry leaders. Event: 2024 BIO International Convention Date: Monday, June 3, 2024 Time: 1:45 p.m. Pacific Time Location: Company Presentation Theater 3 To schedule a meeting with the Company's management at the convention, please submit a meeting request through the BIO One-on-One Partnering™ system or contact Tirth Patel from LHA Investor Relations at tpatel@lhai.com. About Tharimmune Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology. The Company's lead clinical-stage asset, TH104 is known to suppress chronic, debilitating pruritus or "uncontrollable itching" in PBC, a rare and orphan liver disease with no known cure. The Company's early-stage immunology pipeline includes novel multi-specific antibodies targeting unique epitopes with novel mechanisms of action against well-known, validated targets in multiple solid tumors, including PD-1, HER2 and HER3. Tharimmune has a license agreement with OmniAb, Inc. to access the company's antibody discovery technology platform against these and other specified targets. For more information please visit: . Contacts: Tharimmune, Inc. ir@tharimmune.com LHA Investor Relations Tirth T. Patel tpatel@lhai.com 212-201-6614 SOURCE: Tharimmune, Inc. View the original press release on accesswire.com
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.